NCT02923531 - Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

August 8, 2018

Study Completion Date

August 8, 2018

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG

X4P-001

X4P-001 will be administered as per the dose and schedule specified in the arm.

DRUG

Nivolumab

Nivolumab will be administered as per the dose and schedule specified in the arm.

Trial Locations (4)

Washington D.C.

Boston

Hackensack

Chapel Hill